Skip to content
Open access

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer

Sep 2026 · Science · Vol 393, pp. eaeg4791 - eaeg4791 · 1 citation · 115 references
Medicine

TL;DR

It is shown that P-selectin is expressed by a subset of senescent-like cells in fibrotic tissues and tumors, which establishes SMNPs as a generalizable strategy to target pathogenic senescent cell subsets across fibrosis and cancer.

Abstract

Fibrotic remodeling of tissues and tumors establishes immunosuppressive microenvironments that drive organ dysfunction and, in cancer, limit response to immunotherapy. Senescent-like cells are conserved drivers of fibrosis and therapeutic targets, yet their functional heterogeneity complicates therapeutic intervention. Here, we show that P-selectin is expressed by a subset of senescent-like cells in fibrotic tissues and tumors. Leveraging fucoidan-based nanoparticles that bind P-selectin, we developed senescence-modulating nanoparticles (SMNPs) to selectively target these disease-associated states. SMNPs exerted potent antifibrotic and immunomodulatory effects while improving therapeutic index. Mechanistically, we identified a pathogenic, immunosuppressive macrophage population as a functional target in vivo. In fibrotic tumors, niche remodeling restored immune infiltration and sensitized tumors to immune-checkpoint-based therapies. These findings establish SMNPs as a generalizable strategy to target pathogenic senescent cell subsets across fibrosis and cancer.

Read PDF

Similar papers

Review Open access Aug 2026

Immunosuppressive cells as barriers to cancer therapy: mechanisms and emerging solutions

This review offers a comprehensive framework for understanding and surmounting immunosuppressive barriers in cancer therapy and develops systematic synergistic strategies such as multi-pathway checkpoint blockade, ADC-immunotherapy combinations, temporally and spatially optimized conventional therapies, and targeted ag...

Meng-Meng Liu, Yi-Chen Zhu, He-Miao Liang et al. · 0 citations
Review Aug 2026

The senescence-immune axis as a target for combining immunotherapy and senotherapy.

This review focuses on the molecular and cellular mechanisms through which SnCs modulate immune composition and function, emphasizing immune checkpoint ligands, stress-associated surface molecules, and senescence-associated transcriptional programs governing senescence-associated secretory phenotype (SASP) expression.

Fernanda Saez-Calazans, L. Grun, Lucas Emanuel Stein et al. · 0 citations
Review Open access Sep 2026

Smart nanodelivery systems targeting tumor-associated macrophage reprogramming to potentiate cancer immunotherapy: pharmacological mechanisms, delivery strategies and translational perspectives

Smart nanodelivery systems can improve the in vivo stability, tumor accumulation, TAM exposure, and spatiotemporal release of immunomodulators, small-molecule inhibitors, nucleic acid therapeutics, cytokines, and macrophage immune-checkpoint modulators, thereby improving efficacy while reducing systemic toxicity.

Xian-G. Sun, Chen-Chen Chu, Jia-Jie Wang · 0 citations
Review Aug 2026

Ex vivo live macrophage engineering strategies in immunotherapy.

Recent strategies that reprogram and stabilize engineered macrophage phenotypes within the disease environment, and enhance targeting, retention, and contact-dependent functions through engineered recognition modules are reviewed.

Eunha Kim, Min-A Park, Kyobum Kim · 0 citations
Review Open access Oct 2026

Reprogramming the tumor immune landscape through SPP1 targeting

Beyond its canonical roles in bone mineralization and extracellular matrix remodeling, secreted phosphoprotein 1 (SPP1) has emerged as a central regulator of the tumor microenvironment (TME), orchestrating immunosuppressive programs that drive immune evasion and tumor progression. Produced by tumor cells, tumor-assoc...

Li-Xia Gao, Jian-Qiang Yang, Yong Teng · 0 citations
Review Open access Aug 2026

Nanotechnology-enabled immunomodulation in esophageal cancer: targeting the tumor microenvironment to overcome therapeutic barriers

By facilitating the crucial transition from “cold” to “hot” tumors, nanotechnology offers promising potential to amplify antitumor immunity and may contribute to improving clinical outcomes in esophageal cancer.

Qiaoyi Shen, Yi-Bo Gao · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.